Concepedia

Author

Michael I. Walton

Institute of Cancer ResearchORCID

Also Known As

M I Walton, M. I. Walton, M. Walton, M.I. Walton, Michael I Walton, Michael I. Walton, Michael Walton, Michael.I. Walton, Walton, Michael

86

Publications

3.4K

Citations

32

H-Index

76

Concepts

All Affiliations

Institute of Cancer ResearchMRC Cancer UnitCancer Research UKMedical Research CouncilRoyal Marsden Hospital
MI

About

Michael I. Walton is an author at Institute of Cancer Research specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

22

27

1.5K

2

Biochemistry

15

16

822

3

Natural Sciences

10

10

534

4

Engineering

1

1

12

5

Biomolecular Engineering

1

1

30

Michael I. Walton

×

43

Publications

3.2K

Citations

30

H-Index

YearCitations

Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies

Udai Banerji, Anne O’Donnell, Michelle Scurr,

Journal of Clinical Oncology

2005

488

Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis.

Michael I. Walton, D Whysong, Patrick M. O’Connor,

PubMed

1993

276

DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer

Nnennaya Kanu, Maria Antonietta Cerone, Gerald Goh,

Genome biology

2016

168

Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models

Udai Banerji, Michael I. Walton, Florence I. Raynaud,

Clinical Cancer Research

2005

164

Gene and Protein Expression Profiling of Human Ovarian Cancer Cells Treated with the Heat Shock Protein 90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin

Alison Maloney, Paul A. Clarke, Søren Naaby‐Hansen,

Cancer Research

2007

141

<i>In vitro</i> and <i>In vivo</i> Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202

Florence I. Raynaud, Steven R. Whittaker, Peter M. Fischer,

Clinical Cancer Research

2005

129

Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells

Nathalie Gaspar, Swee Y. Sharp, Simon Pacey,

Cancer Research

2009

123

The Role of NAD(P)H: Quinone Reductase (EC 1.6.99.2, DT-Diaphorase) in the Reductive Bioactivation of the Novel Indoloquinone Antitumor Agent E09

Michael I. Walton, Paul J. Smith, Paul Workman

Cancer Communications

1991

122

Effect of p53 Status on Sensitivity to Platinum Complexes in a Human Ovarian Cancer Cell Line

Katharine Pestell, Stephen M. Hobbs, Jenny Titley,

Molecular Pharmacology

2000

111

CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors

Victoria E. Anderson, Michael I. Walton, Paul D. Eve,

Cancer Research

2011

109

Page 1